Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;7(5):2135-2139.
doi: 10.1002/ehf2.12840. Epub 2020 Jul 4.

The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan

Wei-Ting Chang  1   2   3 , Yin-Hsun Feng  4 , Yu Hsuan Kuo  4 , Wei-Yu Chen  4 , Hong-Chang Wu  4 , Chien-Tai Huang  4 , Wen-Ching Wang  5 , Chia-Te Liao  1 , Zhih-Cherng Chen  1
Affiliations
Editorial

The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan

Wei-Ting Chang et al. ESC Heart Fail. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
In contrast to a continuous drop of left ventricular ejection fraction (LVEF) in the non‐cardio‐oncology programme, the decline of LVEF was mitigated in patients under the cardio‐oncology programme. (Grey bar: non‐cardio‐oncology programme, N = 154; black bar: cardio‐oncology programme, N = 450).
Figure 2
Figure 2
Before cardio‐oncology programme, there were 1.7% of new‐onset hypertension (HTN), 1% of new‐onset heart failure (HF), 0.9% of myocardial infarction (MI), 0.9% of ischemic stroke, and 16.8% of mortality. Conversely, after the programme, there were only 0.6% of new‐onset hypertension while no other cardiovascular complications were reported.
See this image and copyright information in PMC

References

    1. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013; 113: 754–764. - PMC - PubMed
    1. Campia U, Moslehi JJ, Amiri‐Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL. Cardio‐oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation 2019; 139: e579–e602. - PMC - PubMed
    1. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, Baksi AJ, Khattar RS, Sharma R, Rosen SD, Lyon AR. Activity and outcomes of a cardio‐oncology service in the United Kingdom—a five‐year experience. Eur J Heart Fail 2018; 20: 1721–1731. - PubMed
    1. Kim H, Chung WB, Cho KI, Kim BJ, Seo JS, Park SM, Kim HJ, Lee JH, Kim EK, Youn HJ. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti‐cancer treatment in clinical practice: an opinion paper from the working group on cardio‐oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound 2018; 26: 1–25. - PMC - PubMed
    1. Henry ML, Niu J, Zhang N, Giordano SH, Chavez‐MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy‐treated breast cancer patients. J Am Coll Cardiol Img 2018; 11: 1084–1093. - PMC - PubMed

Publication types